Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Jill Kolesar; Wei Huang; Jens Eickhoff; Kristine Hahn; Dona Alberti; Steven Attia; William Schelman; Kyle Holen; Anne Traynor; Percy Ivy; George Wilding

doi:10.1007/s00280-008-0845-0

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Jill Kolesar, Wei Huang, Jens Eickhoff, Kristine Hahn, Dona Alberti, Steven Attia, William Schelman, Kyle Holen, Anne Traynor, Percy Ivy, George Wilding

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.

Original language	English
Pages (from-to)	79-86
Number of pages	8
Journal	Cancer Chemotherapy and Pharmacology
Volume	64
Issue number	1
DOIs	https://doi.org/10.1007/s00280-008-0845-0
State	Published - Jun 2009

Bibliographical note

Funding Information:
Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).

Funding

Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).

Funders	Funder number
National Institutes of Health (NIH)	T32 CA009614
National Childhood Cancer Registry – National Cancer Institute	24XS090, U01CA062491
National Center for Research Resources	UL1RR025011

Keywords

3-Aminopyridine-2-carboxaldehyde thiosemicarbazone
Automated quantitative immunohistochemistry (AQUA)
Quantitative real time PCR
Ribonucleotide reductase
Triapine

ASJC Scopus subject areas

Oncology
Toxicology
Pharmacology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00280-008-0845-0

Cite this

@article{5ecb8d8422cb440bb008271e25d54242,

title = "Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors",

abstract = "Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.",

keywords = "3-Aminopyridine-2-carboxaldehyde thiosemicarbazone, Automated quantitative immunohistochemistry (AQUA), Quantitative real time PCR, Ribonucleotide reductase, Triapine",

author = "Jill Kolesar and Wei Huang and Jens Eickhoff and Kristine Hahn and Dona Alberti and Steven Attia and William Schelman and Kyle Holen and Anne Traynor and Percy Ivy and George Wilding",

note = "Funding Information: Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).",

year = "2009",

month = jun,

doi = "10.1007/s00280-008-0845-0",

language = "English",

volume = "64",

pages = "79--86",

number = "1",

}

TY - JOUR

T1 - Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

AU - Kolesar, Jill

AU - Huang, Wei

AU - Eickhoff, Jens

AU - Hahn, Kristine

AU - Alberti, Dona

AU - Attia, Steven

AU - Schelman, William

AU - Holen, Kyle

AU - Traynor, Anne

AU - Ivy, Percy

AU - Wilding, George

N1 - Funding Information: Acknowledgments Supported by: U01CA062491 “Early Clinical Trials of Anti-Cancer Agents with Phase I Emphasis” NCI; CTEP Translational Research Initiative Funding 24XS090, and 1ULRR025011. Clinical and Translational Science Award of the National Center for Research Resources, NIH; and NIH grant T32 CA009614. Physician Scientist Training in Cancer Medicine (Dr. Attia).

PY - 2009/6

Y1 - 2009/6

N2 - Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.

AB - Purpose: The purpose of this study was to evaluate baseline RRM2 protein and gene expression in tumors of patients receiving 3-AP. Methods: Tumor blocks from patients enrolled in phase I and II clinical studies using 3-AP, were evaluated for RRM2 gene and protein expression by quantitative real time polymerase chain reaction (Q-RTPCR) and automated quantitative analysis (AQUA). Results: Esophageal and gastric cancers overexpressed RRM2 protein when compared to prostate cancer (Z-score, 0.68 ± 0.94 SD, vs 0.41 ± 0.84 SD, respectively; p = 0.04). Esophageal and gastric cancers also overexpressed RRM2 mRNA when compared to prostate cancer (relative gene expression 2.56 ± 1.49 SD, vs 0.29 ± 0.20 SD, respectively; p = 0.02). Protein and gene expression were moderately associated (Spearman's rank correlation = 0.30; p = 0.12). Conclusion: RRM2 gene and protein expression varies by tumor type.

KW - 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone

KW - Automated quantitative immunohistochemistry (AQUA)

KW - Quantitative real time PCR

KW - Ribonucleotide reductase

KW - Triapine

UR - http://www.scopus.com/inward/record.url?scp=67349119922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349119922&partnerID=8YFLogxK

U2 - 10.1007/s00280-008-0845-0

DO - 10.1007/s00280-008-0845-0

M3 - Article

C2 - 18941749

AN - SCOPUS:67349119922

SN - 0344-5704

VL - 64

SP - 79

EP - 86

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

ER -

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this